Drug Trial Radar · NCT06375343
Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive®
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Jul 30, 2027
Primary completion
Mar 30, 2028
Study completion Apr 30, 2028
Sponsor
- Lead sponsor
- Laboratorios Sophia S.A de C.V.Industry
- Sponsor type
- Industry
- First posted
- Apr 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a phase I clinical study to evaluating safety and tolerability of PRO-240 ophthalmic solution through the incidence of unexpected adverse events, as well as through changes in Best Corrected Visual Acuity (BCVA), and the incidence of stinging after its administration, compared to Optive®.
Conditions
- Dry Eye Disease
- Dry Eye Sensation
- Ocular Surface Disease
Interventions
PRO-240Drug
-Propylene glycol 0.3%, Polyethylene glycol 400 0.5%, and Glycerin 0.2%. Ophthalmic solution.
Optive®Drug
\- Carboxymethylcellulose 0.5%, and Glycerin 0.9%. Ophthalmic solution.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of unexpected adverse events related to the interventionsTime frame: Days 0: (Basal Visit), 8 (Final Visit) and 11 (Safety Call)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.